Conor Kilroy, who serves as Chief Legal Officer and Secretary at Aura Biosciences, executed a sale of 11,738 shares of the company's common stock on April 16, 2026. The transactions occurred at prices between $7.02 and $7.05 per share, producing an aggregate proceeds figure of roughly $82,400.
The disposition was disclosed on a Form 4 filing and, according to that filing, reflects the number of shares needed to satisfy tax withholding requirements arising from the vesting of restricted stock units. The Form 4 notes the sales were automatic and not at Kilroy's discretion.
Following the sale, Kilroy retains direct ownership of 217,835 shares of Aura Biosciences. The stock has appreciated about 30% so far this year and is trading close to its 52-week high of $7.48.
Market commentary presents a mixed picture. InvestingPro's analysis indicates the stock appears overvalued relative to its Fair Value. At the same time, analysts tracked in the consensus maintain optimistic price targets, which range from $15 to $26.
Analyst attention and clinical update
Among sell-side firms, H.C. Wainwright reiterated a Buy rating on Aura's shares and set a $22.00 price target. The firm called out progress in the company's bel-sar franchise, specifically citing accelerating enrollment in the global Phase 3 CoMpass trial for early choroidal melanoma. H.C. Wainwright noted the trial is expected to complete enrollment by mid-2026, with a topline 15-month data readout anticipated in the second half of 2027.
The analyst commentary also highlights regulatory milestones: the bel-sar program holds Fast Track and Orphan Drug designations from both the U.S. Food and Drug Administration and the European Medicines Agency, according to the note.
Context and implications
The sale by Kilroy was routine in the context of RSU vesting and related tax obligations, and the Form 4 disclosure makes clear the transactions were not voluntary exercises of discretion. The stock's recent run and the divergence between InvestingPro's Fair Value assessment and analyst price targets underline a tension between market momentum and model-based valuation.
Information about ownership levels, valuation perspectives, analyst targets and trial timelines is based on the disclosures and analyst commentary contained in the public filings and research noted above.